Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer

Drs. Catherine Marshall, Melissa Reimers, and Tanya Dorff share their thoughts on ordering somatic versus germline testing for patients with advanced prostate cancer, PARP inhibitor treatment strategies for BRCA-mutated patients throughout the care continuum, and treatment considerations for patients with other HRD pathway mutations.

The trio respond to questions pertaining to the currently identified mutations on NGS, what the guideline say about when and for whom to order genetic testing, and challenges related to bone biopsies, age of prostate tissue, and more.

View their continued comments on Toxicities From Single-Agent, Combination PARP Inhibitors for Advanced Prostate Cancer.